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Abstract
Malabsorption as a result of decreased intestinal function is a frequently occurring problem in
intensive care units. Small bowel dysfunction may lead to malnutrition and may predispose patients to
infectious complications (sepsis) and may be linked to increased hospitalization duration, morbidity
and mortality. There are several small bowel function tests, such as faecal fat excretion and sugar
absorption tests, but data specifically applicable to the intensive care setting are limited. Moreover,
there are multiple confounders such as altered intestinal permeability, changed transit time and renal
dysfunction. A more specific test, fasting plasma citrulline concentration, has poor test characteristics
for detection of decreased intestinal function in patients with dysfunctional enterocytes. Therefore, a
citrulline generation test was recently developed in order to measure the conversion of glutamine
(administered either enterally or intravenously) into citrulline. This conversion takes place exclusively
in a properly functioning enterocyte; therefore, citrulline generation upon glutamine stimulation may
be a promising biomarker for assessment of the small bowel function.
Introduction and context
Malabsorption in intensive care unit (ICU) patients is
arbitrarily defined as an intestinal absorption capacity of
85% or less. It is believed to be a frequently occurring
problem in ICUs, particularly in patients suffering from
sepsis or multiple organ dysfunction [1,2]. Malabsorp-
tion is the most important clinical sign of intestinal
dysfunction or failure, reflecting various altered aspects
of intestinal physiology due to a diseased state. Some of
these altered aspects are coordinated intestinal transport
(motility) and coordinated exocrine digestive functions
of various organs like the pancreas, liver and jejunum
(enterocytes). Other factors involve the intestinal wall
function, like mucosal immunological response and
intestinal barrier function, as well as visceral blood flow.
Critically ill patients may be prone to a reduced
enterocyte function due mainly to a reduced splanchnic
blood flow. This dysfunction may subsequently con-
tribute to (the alleged) bacterial translocation and
ultimately sepsis and multi-organ dysfunction syndrome
(MODS) [3,4]. Simple, clear-cut and validated tests to
assess these various aspects of coordinated physiological
functions of digestion are not available at the bedside.
Nevertheless, adequate absorption of food is paramount
to the improvement of the patient’s condition and to the
outcome of the critically ill patient [5]. This concise
review aims to emphasize the importance of diagnosing
malabsorption and to give new insights into how to
assess intestinal function.
Current tests
In critically ill patients, it may be cumbersome to assess
the various aspects of digestion as there are no validated
tests to quantify the small bowel function. To meet
this challenge, we tend to approach the problem as a
failure of the intestinal tract comparable with other
organ failures as a part of MODS (such as renal failure).
However, a simple blood test or marker such as creati-
nine or BUN (blood urea nitrogen) levels is lacking in the
evaluation of intestinal function. Thus, secondary vari-
ables, such as measurement of intestinal barrier function
and intestinal absorption, are usually applied. Relatively
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absorption test (SAT), quantification of fat excretion in
stools (FES) and bomb calorimetry (BC).
Sugar absorption test
Gastrointestinal permeability can be measured by the
SAT. During this test, a solution of multiple saccharides
is orally administered [6-8]. The applied saccharides
have different molecule sizes and are specifically chosen
as these cannot be metabolized in the human body. The
tight junctions in the tip of the villi allow translocation
of small saccharides, whereas translocation of larger
saccharides is restricted to the crypts [6]. In a normally
functioning small bowel, the permeability for small
saccharides is higher than for larger saccharides. How-
ever, under pathological conditions, the permeability for
small saccharides decreases whereas the permeability for
larger saccharides increases [7]. The amount of renally-
excreted saccharides (particularly the large saccharide/
small saccharide ratio) is an indicator of small bowel
absorptive function [7,8]. There are some flaws in this
test. By means of SAT, intestinal (paracellular) perme-
ability rather than (metabolic) enterocyte function is
assessed [7]. In addition, Oudemans-van Straaten et al.
[9] reported that the SAT is unreliable when used on
ICU patients with multiple organ failure because there
are various non-permeability-related confounders, such
as impaired renal function and diminished intestinal
motility. Also, oliguria/anuria limits its use in daily ICU
practice.
Quantification of fat excretion in stools
This test aims to quantify the FES. The patient is given a
dietcontainingaknownhighamountoffattosaturatethe
intestinal mechanisms and to challenge the intestinal
maximalabsorptivecapacity.Duringthisdiet,thepatient’s
faeces are sampled for 24 hours or, preferably, 72 hours.
The amount of faecal fat can be measured by the Van de
Kamer method, which allows the calculation of fat
absorption capacity [10]. The underlying concept of FES
is that malabsorption of fat correlates with malabsorption
in general. However, Wierdsma and van Bodegraven [11]
found that not all malabsorption states are detected by
measuring fat in faeces. Faecal carbohydrate loss signifi-
cantly contributed to the malnutrition state, and this
contribution is overlooked by looking merely at FES [11].
Bomb calorimetry
Faecal energy is measured by combustion of a faecal
sample and subsequent calculation of 72 hours of faecal
energy loss, which is considered the (alleged) gold
standard for intestinal digestive function [12,13]. Com-
bining the energy (caloric) intake and the faecal energy
loss into a formula allows the calculation of intestinal
energy absorption (percentage). Again, data are scarce,
specifically in the critically ill, in whom BC is hampered
by problems with reliable collection of faeces during a
full 3-day period [1].
Recent advances
Citrulline is an amino acid that is produced almost
entirely from glutamine in the enterocytes. Because this
conversion can take place only in a functioning
enterocyte, citrulline has been proposed as an attractive
and promising biomarker to assess the function of the
small intestine [14,15]. Previous studies reported the
value of fasting plasma citrulline concentration as a
biomarker for enterocyte (intestinal) mass in a wide
array of intestinal diseases such as coeliac disease,
Crohn’s disease, short bowel syndrome and radiation
enteritis,andinrecipientsofintestinaltransplants[16-21].
Recently, however, fasting plasma citrulline concentra-
tion was found to be a poor predictor of the clinical
relevance of decreased intestinal function in patients
with short bowel syndrome and, in other words, failed
to predict long-term dependence on total parenteral
nutrition [22,23].
Citrulline generation test
The citrulline generation test (CGT) is a recently
developed test to dynamically measure the conversion
of glutamine into citrulline over time, following admin-
istration of glutamine as a dipeptide with alanine
(Dipeptiven). Through the administration of a large
quantity of glutamine-alanine, the capacity of this
enterocytic metabolic pathway is challenged, and this
challenge is manifested by a decreased conversion in
patients with a decreased enterocyte mass. The CGT is
validated in various intestinal diseases [14]. In practice,
following a slow intravenous injection of 100 mL of
glutamine-alanine, multiple blood samples are drawn at
different times to determine the increment (in other
words, generation) in serum level of citrulline by using
reverse-phase high-performance liquid chromatography
[24]. The CGT is easily applied in patients with suspected
small bowel dysfunction. The citrulline generation [as
defined by either the citrulline increase or the AUC (area
under the curve)] correlates closely with enterocyte mass
and enterocyte function and reflects the amount of
functioning enterocytes to generate citrulline. In stable
ICU patients, preliminary results from our own group
indicate a reduced enterocyte mass that was associated
with disease severity.
Implications for clinical practice
The small intestine has many functions, two of which are
of major importance in the setting of critical illness:
nutrient and energy absorption and function of the
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nutrients,wateranddrugsisanessentialpartofimproving
or regaining health [5]. Malnutrition and insufficient
bioavailability of drugs can increase hospitalization stay,
morbidity, mortality and costs [5]. The intestinal barrier
function is a very important intestinal feature that keeps
bacteria from translocating into the blood and thus
prevents sepsis from originating from the gut [3,4].
It is obvious that dysfunction of the small intestine may
have serious consequences and that identifying those
patients who are at risk for developing malabsorption or
those who are already malnourished is therefore pivotal.
The most common applied intestinal function tests –
faecal, urine and blood tests alike – all have several major
flaws (in particular in very ill patients), which prevent
these tests from being used and render it very difficult to
accurately quantify intestinal function in the ICU setting.
The CGT, a more functional test, measures the enterocyte
function and is likely to play an important role in the
assessment of intestinal function in the future. The CGT
is relatively easy to perform but warrants further
validation in several ICU patient cohorts by comparing
it with one or more of the other small bowel function
tests and by taking nutritional status into account.
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